Funded Biotechnology Startups in New Haven
New Haven's biotechnology funding record in this dataset spans from June 2020 through August 2025, with Arvinas closing the most recent round — undisclosed…
New Haven's biotechnology funding record in this dataset spans from June 2020 through August 2025, with Arvinas closing the most recent round — undisclosed — in August 2025, and D2B3 raising a $500K Pre-Seed in April 2025. The largest single raise belongs to Biohaven Pharmaceutical, which secured $302M in a Post-IPO Equity round in October 2022, a figure that substantially outpaces every other round in this set.
Activity was notably concentrated in 2020–2021, when Simcha Therapeutics ($25M), Cybrexa Therapeutics ($25M Series B), Allyx Therapeutics ($8M), and Biorez ($4M) all closed within a 15-month window. More recent vintages trend smaller: Seranova Bio's $10M in February 2024 and Precipio Diagnostics's $500K in May 2024 represent the 2024 cohort. Round-type transparency is uneven — four companies carry a Series Unknown classification and three show no stage label — so stage-based filtering on this segment will surface incomplete coverage.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed rounds among New Haven biotech companies in this set?
Biohaven Pharmaceutical leads with a $302M Post-IPO Equity raise in October 2022. The next largest are Cybrexa Therapeutics ($25M Series B, March 2021) and Simcha Therapeutics ($25M, June 2020), with Seranova Bio's $10M round in February 2024 the most recent raise above single-digit millions.
Which companies have raised most recently?
Arvinas closed an undisclosed round in August 2025, making it the most recent in this dataset. D2B3 followed with a $500K Pre-Seed in April 2025, and Precipio Diagnostics and Seranova Bio both raised in 2024 — $500K and $10M respectively.
What funding stages are represented here?
The dataset includes Pre-Seed (D2B3), Series B (Cybrexa Therapeutics), and Post-IPO Equity (Biohaven Pharmaceutical). Four companies carry a Series Unknown classification, meaning disclosed amounts exist but stage labels were not reported, and three rounds have no stage listed at all.
Are any of these companies already public?
Biohaven Pharmaceutical raised $302M in a Post-IPO Equity round in October 2022, indicating it had already completed an IPO by that date. No other company in the visible dataset shows a post-IPO round type.
How wide is the range of raise sizes in this segment?
Disclosed amounts span from $500K — raised by both D2B3 and Precipio Diagnostics — up to $302M for Biohaven Pharmaceutical. Excluding that outlier, most rounds in the set fall between $500K and $25M. Arvinas's August 2025 round is undisclosed, so its size is not reflected in any range.
Are all these companies actually located in New Haven, Connecticut?
Nine of the ten companies list New Haven, Connecticut as their location. Allyx Therapeutics is the exception, recorded as New Haven, New York, which may reflect a data entry variation or a distinct operating address.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.